SRPK2 activation promotes pathogenic LPIN1 splicing, to the lipogenic lipin‐1β isoform via SRSF10, in alcohol‐associated liver disease; genetic or pharmacological inhibition of SRPK2 reduces hepatic steatosis [216]. Here, SRPK2 is linked to fatty liver disease.